Literature DB >> 12836056

Peptides with anticancer use or potential.

Y L Janin1.   

Abstract

This review is an attempt to illustrate the diversity of peptides reported for a potential or an established use in cancer therapy. With 612 references, this work aims at covering the patents and publications up to year 2000 with many inroads in years 2001-2002. The peptides are classed according to four categories of effective (or plausible) biological mechanisms of action: receptor-interacting compounds; inhibitors of protein-protein interaction; enzymes inhibitors; nucleic acid-interacting compounds. The fifth group is made of the peptides for which no mechanism of action has been found yet. Incidentally this work provides an overview of many of the modern targets of anticancer research.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12836056     DOI: 10.1007/s00726-002-0349-x

Source DB:  PubMed          Journal:  Amino Acids        ISSN: 0939-4451            Impact factor:   3.520


  9 in total

1.  Effects of dimerization on the structure and biological activity of antimicrobial peptide Ctx-Ha.

Authors:  E N Lorenzón; G F Cespedes; E F Vicente; L G Nogueira; T M Bauab; M S Castro; E M Cilli
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

2.  In silico design of tubulin-targeted antimitotic peptides.

Authors:  Stefano Pieraccini; Giorgio Saladino; Graziella Cappelletti; Daniele Cartelli; Pierangelo Francescato; Giovanna Speranza; Paolo Manitto; Maurizio Sironi
Journal:  Nat Chem       Date:  2009-10-23       Impact factor: 24.427

3.  A strategy for dual inhibition of the proteasome and fatty acid synthase with belactosin C-orlistat hybrids.

Authors:  Mingzhao Zhu; Wayne D Harshbarger; Omar Robles; Joanna Krysiak; Kenneth G Hull; Sung Wook Cho; Robyn D Richardson; Yanyan Yang; Andres Garcia; Lindsey Spiegelman; Bianca Ramirez; Christopher T Wilson; Ju Anne Yau; James T Moore; Caitlen B Walker; James C Sacchettini; Wenshe R Liu; Stephan A Sieber; Jeffrey W Smith; Daniel Romo
Journal:  Bioorg Med Chem       Date:  2017-01-19       Impact factor: 3.641

4.  A missense mutation in Caenorhabditis elegans prohibitin 2 confers an atypical multidrug resistance.

Authors:  Iryna Zubovych; Thomas Doundoulakis; Patrick G Harran; Michael G Roth
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-10       Impact factor: 11.205

5.  β-Actin-binding complementarity-determining region 2 of variable heavy chain from monoclonal antibody C7 induces apoptosis in several human tumor cells and is protective against metastatic melanoma.

Authors:  Denise C Arruda; Luana C P Santos; Filipe M Melo; Felipe V Pereira; Carlos R Figueiredo; Alisson L Matsuo; Renato A Mortara; Maria A Juliano; Elaine G Rodrigues; Andrey S Dobroff; Luciano Polonelli; Luiz R Travassos
Journal:  J Biol Chem       Date:  2012-02-13       Impact factor: 5.157

6.  Anticancer activity of a peptide combination in gastrointestinal cancers targeting multiple neuropeptide receptors.

Authors:  Manu Jaggi; Sudhanand Prasad; Anu T Singh; R Praveen; Sarjana Dutt; Archana Mathur; Rajan Sharma; Neena Gupta; Rinku Ahuja; Rama Mukherjee; Anand C Burman
Journal:  Invest New Drugs       Date:  2008-01-24       Impact factor: 3.850

7.  Efficacy of continuously administered PEDF-derived synthetic peptides against osteosarcoma growth and metastasis.

Authors:  Matthew L Broadhead; Peter F M Choong; Crispin R Dass
Journal:  J Biomed Biotechnol       Date:  2012-05-30

8.  Identification of the sAPRIL binding peptide and its growth inhibition effects in the colorectal cancer cells.

Authors:  Xiao-qing He; Jing Guan; Fang Liu; Jing Li; Mei-rong He
Journal:  PLoS One       Date:  2015-03-31       Impact factor: 3.240

9.  AC-1001 H3 CDR peptide induces apoptosis and signs of autophagy in vitro and exhibits antimetastatic activity in a syngeneic melanoma model.

Authors:  Aline N Rabaça; Denise C Arruda; Carlos R Figueiredo; Mariana H Massaoka; Camyla F Farias; Dayane B Tada; Vera C Maia; Pedro I Silva Junior; Natalia Girola; Fernando Real; Renato A Mortara; Luciano Polonelli; Luiz R Travassos
Journal:  FEBS Open Bio       Date:  2016-07-15       Impact factor: 2.693

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.